Digital twin to personalize acute myeloid leukemia treatment
Prototype System for AML Digital Twins
This project builds a virtual copy of an adult's AML using their blood and bone marrow data so doctors can try out treatment options on the model before giving them to the patient.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Institute for Systems Biology NIH-funded |
| Lab location | 1 site (Seattle, United States) |
| Project ID | NIH-11492240 on NIH RePORTER |
What this research studies
You would give blood and a bone marrow sample so researchers can use your clinical and molecular data to create a personalized computer model of your leukemia. That digital twin simulates how your cancer might respond to different drugs so you and your doctor can explore likely outcomes without real-world risk. The system is designed to be interactive, showing predicted responses and helping guide treatment conversations. The work focuses on adults with AML and aims to help especially patients who have relapsed or cannot tolerate intensive chemotherapy.
Who could benefit from this research
Good fit: Adults (21+) with acute myeloid leukemia who can provide peripheral blood and bone marrow samples, especially those with relapsed/refractory disease or those weighing treatment options, are the best candidates.
Not a fit: Children, people who cannot provide required samples, or anyone needing immediate emergency treatment are unlikely to benefit from this prototype system.
Why it matters
Potential benefit: If successful, this could help your doctor choose treatments that are more likely to work for your specific AML and avoid ineffective or toxic options.
How similar studies have performed: Digital twin methods are new in medicine — early modeling work shows promise but patient-level AML digital twins are largely experimental and not yet proven in trials.
Where this research is happening
Seattle, United States
- Institute for Systems Biology — Seattle, United States (Active)
Researchers
- Principal investigator: Thorsson, Vesteinn — Institute for Systems Biology
- Study coordinator: Thorsson, Vesteinn
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.